Showing results (71-80 of 305) with videos related to
Sort By:
Pageof 31
Future Oncology (London, England)|June 2, 2018
The role of niraparib for the treatment of ovarian cancerJosee-Lyne Ethier, Stephanie Lheureux, Amit M OzaJournal of Analytical Toxicology|April 13, 2001
Cobas Mira S endpoint enzymatic assay for plasma formateB Blomme, P Lheureux, E Gerlo, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 5, 2020
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairPanagiotis A Konstantinopoulos, Stephanie Lheureux, Kathleen N MooreClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
DNA Methylation as a Robust Classifier of Epithelial Ovarian CancerCharles A Ishak, Stephanie Lheureux, Daniel D De CarvalhoHuman & Experimental Toxicology|March 1, 1990
Zolpidem intoxication mimicking narcotic overdose: response to flumazenilP Lheureux, G Debailleul, O De Witte, et al.Expert Opinion on Drug Safety|June 9, 2015
Safety evaluation of olaparib for treating ovarian cancerStephanie Lheureux, Valerie Bowering, Katherine Karakasis, et al.Biochemical and Biophysical Research Communications|July 18, 1997
Overexpression of a 40-kDa protein in human multidrug resistant cellsY Wang, X Q Pan, F Lheureux, et al.Lancet (London, England)|March 27, 2019
Epithelial ovarian cancerStephanie Lheureux, Charlie Gourley, Ignace Vergote, et al.Cancers|March 10, 2022
Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic CancersLawrence Kasherman, Shiru Lucy Liu, Katherine Karakasis, et al.The International Journal of Developmental Biology|March 1, 1990
Cell interactions and regeneration controlB Boilly, E Lheureux, Y Boilly-Marer, et al.Pageof 31